With more than $1 billion in damages on the line, a Texas jury rejected a whistleblower's claims that Abbott Laboratories violated the False Claims Act by improperly marketing bile duct stents, according to FierceMedicalDevices.
A salesman for Guidant, a company acquired by Abbott in 2006, accused the company of marketing bile duct stents intended for short-term use for complex cases. During the three-week trial, defense attorneys argued that using biliary stents for peripheral vascular or arterial disease was an accepted medical practice. Article